Develops gene therapies for severe genetic diseases of the central nervous system, with a treatment in development for Rett syndrome.
10-K for FY2025, filed Mar 19, 2026
Revenue comes from activities under the Astellas Transactions, including an exclusive option to license intellectual property and research and development work.
10-K for FY2025, filed Mar 19, 2026The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, (“ASC 606”). Revenues consist of…View ↗
$9.8M
10-K for FY2025, filed Mar 19, 2026
$9.8M ↗No. It lost $109M in FY2025.
A narrower pipeline focus
The older report described candidates for giant axonal neuropathy and other neurological conditions; the latest centers on Rett syndrome and frames the rest of its central nervous system pipeline as future opportunities.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026We are focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the CNS, in both…View ↗
Loading...